Evidence map›Paper›PMID 19368560›Full record

ReviewImmunology2009

The companions: regulatory T cells and gene therapy.

Saman Eghtesad, Penelope A Morel, Paula R Clemens

Abstract readReview
In one paragraph

Review in Immunology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. HLA Polymorphism Affects Risk ofFrontiers in neurology · 2018
    Article
  3. Article
  4. Changes in chemokine receptor expression of regulatory T cells after ex vivo culture.Journal of immunotherapy (Hagerstown, Md. : 1997) · 2012
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Saman EghtesadDepartment of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
Penelope A Morel
Paula R Clemens

Funding

Inducing Tolerance to Gene Transfer in Dystrophic MiceF31NS056780 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI EGHTESAD, SAMAN · 2008 to 2010
$111k
NINDS NIH HHS 1-F31-NS056780-01A2NINDS NIH HHS F31 NS056780
6 · The paper itself

Abstract

Undesired immunological responses to products of therapeutic gene replacement have been obstacles to successful gene therapy. Understanding such responses of the host immune system to achieve immunological tolerance to a transferred gene product is therefore crucial. In this article, we review relevant studies of immunological responses to gene replacement therapy, the role of immunological tolerance mediated by regulatory T cells in down-regulating the unwanted immune responses, and the interrelationship of the two topics.

Indexed as

Genetic TherapyHumansImmune ToleranceMaleMuscular Dystrophy, DuchenneT-Lymphocytes, Regulatory

Identifiers

PMID19368560
PMCPMC2678176

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.